ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
J&J goes straight into phase 3 in prostate
The company is to test its KLK2-targeting pasritamig in a late-line setting.
ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
ASCO 2024 preview – toxicity looms large for J&J
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
